You are here: Industry Insights > Hemlibra

News List

New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A expresspharma
July 21, 2021
Final analysis from the phase-IIIb STASEY study, including data from 193 people with haemophilia A, further supports the benefit/risk profile of Hemlibra, with no new safety signals identified.
JW Pharmaceutical gains Korean approval for Hemlibra firstwordpharma
January 21, 2019
JW Pharmaceutical said Sunday that it gained the South Korean drug regulator's approval to begin domestic sales of the hemophilia treatment Hemlibra, developed by Roche's Chugai unit, reported The Korea Herald.
Hemlibra shows "clinically meaningful" bleed control in paediatric haemophilia A patients pharmafile
December 07, 2018
In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for Hemlibra (emicizumab) as a prophylactic in haemophilia A patients
Roche's Hemlibra shows sustained bleed control in children pharmatimes
December 06, 2018
Roche's Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A.
Gene therapy firm BioMarin stages haemophilia musical pharmaphorum
November 27, 2018
BioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression helps patients, as it develops an experimental cure for the condition.
FDA expands indication of Roche's Hemlibra in haemophilia pharmafile
November 20, 2018
The FDA has chosen to expand the label of Roche’s Hemlibra (emicizumab-kxwh), approving it for routine prophylaxis to prevent the frequency
Use of Roche’s haemophilia A therapy Hemlibra expanded in the US pharmatimes
October 11, 2018
Roche’s Hemlibra has been approved in the US for routine prophylaxis of bleeding episodes patients with haemophilia A without factor VIII inhibitors.
Roche’s Hemlibra secures extended FDA approval for haemophilia A pharmaceutical-technology
October 09, 2018
Roche has secured approval from the US Food and Drug Administration (FDA) for the use of Hemlibra (emicizumab-kxwh) to treat haemophilia A patients without factor VIII inhibitors.
Five Deaths in Genentech's Hemlibra Patients biospace
March 29, 2018
The American Hemophilia Federation and the National Hemophilia Foundation announced that they have contacted Genentech, a Roche company
Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibito roche
December 11, 2017
Newly approved Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents as prophylaxis or on-demand

Previous page 1 2 Next page